Home » Stocks » HZNP

Horizon Therapeutics PLC (HZNP)

Stock Price: $101.05 USD 0.98 (0.98%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $100.80 -0.25 (-0.25%) Jul 23, 7:01 PM
Market Cap 23.09B
Revenue (ttm) 2.19B
Net Income (ttm) 280.04M
Shares Out 224.77M
EPS (ttm) 1.25
PE Ratio 80.78
Forward PE 19.80
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $101.05
Previous Close $100.07
Change ($) 0.98
Change (%) 0.98%
Day's Open 100.76
Day's Range 99.88 - 103.03
Day's Volume 1,610,935
52-Week Range 58.06 - 103.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Stock Indexes Edge Higher, Sit Near All-Time Highs; CrowdStrike, Horizon Therapeutics, Global-E O.

YouTube video

Stock indexes edge higher, sit near all-time highs; CrowdStrike, Horizon Therapeutics, Global-E Online in focus. Investor's Business Daily has been helping people invest smarter results by providing exc...

Other stocks mentioned: CRWD, GLBE
1 day ago - Investors Business Daily

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Fortune Best Workplaces for Millennials™ list for the second consecutive year. Horizon...

1 week ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2021 financial results will be released on Wednesday, Aug. 4, 2021. Following the announcement, H...

2 weeks ago - Business Wire

Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.

3 weeks ago - Zacks Investment Research

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it will host a virtual R&D Day for investors and analysts on Wednesday, Sept. 29, 2021 at 8 a.m. CT. Horizon's R&D D...

3 weeks ago - Business Wire

If production setbacks can be avoided, gains should be in sight.

Other stocks mentioned: CTLT, OPK
3 weeks ago - The Motley Fool

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734 (formerly VIB7734),...

3 weeks ago - Business Wire

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pa...

Other stocks mentioned: ARWR
1 month ago - Benzinga

PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) today announced a global collaboration and license agreement for ARO...

Other stocks mentioned: ARWR
1 month ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during t...

1 month ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has reached an agreement to purchase a drug product manufacturing facility from EirGen Pharma, an OPKO Health Com...

1 month ago - Business Wire

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today presented new data during the EULAR European Congress of Rheumatology from the ongoing PROTECT study, which provides further insigh...

1 month ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEXXA (pegloticase injection) w...

1 month ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming conferences: Jefferies Virtual Health Care Conference Date: T...

2 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced data presentations at the EULAR European Congress of Rheumatology, June 2 – 5, 2021. At this year's meeting, Horizon will...

2 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the Great Place to Work® Best Workplaces in Chicago 2021 list, ranking No. 13 in the large comp...

2 months ago - Business Wire

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...

Other stocks mentioned: CERC, CRSP, JNJ, LLY, SDGR, TAK
2 months ago - InvestorPlace

DUBLIN--(BUSINESS WIRE)--Horizon ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company.

2 months ago - Business Wire

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...

Other stocks mentioned: ALLK, IBRX, IMAB, MNMD, SAGE, SWTX
2 months ago - InvestorPlace

As investors were so righteously reminded on Friday, many of the day-to-day Wall Street prognostications and strategy calls are almost always “best guesses” or data-based “assumptions.

Other stocks mentioned: FCX, TLRY, Z
2 months ago - 24/7 Wall Street

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in May: Bank of America Securities 2021 Health Care Confere...

2 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--New analysis of UPLIZNA® (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD) has been published.

2 months ago - Business Wire

Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.

2 months ago - Zacks Investment Research

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, has been named a 2021 Healthcare...

2 months ago - Business Wire

Horizon Therapeutics reported a mixed quarter Wednesday, but raised its sales target for 2021. Still, HZNP stock dipped after the open.

2 months ago - Investors Business Daily

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -57.14% and 4.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 92.50% year over year to $0.03, which missed the estimat...

2 months ago - Benzinga

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Guidance to Incorporate Recently Acquired Viela Bio

2 months ago - Business Wire

Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 months ago - Zacks Investment Research

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc ranked #4 in overall corporate reputation among pharmaceutical and biotech companies.

2 months ago - Business Wire

CHARLOTTESVILLE, Va., April 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout un...

3 months ago - PRNewsWire

NAARDEN, The Netherlands & MUNICH--(BUSINESS WIRE)--Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I (“Forbion G...

3 months ago - Business Wire

Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug.

3 months ago - The Motley Fool

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics today announced new UPLIZNA® (inebilizumab-cdon) data being presented at the American Academy of Neurology 2021 Annual Meeting.

3 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology.

3 months ago - Business Wire

Biotech stock Horizon Therapeutics is set up below a buy point, ahead of earnings, after soaring 102% in 2020. Can it do it again?

3 months ago - Investors Business Daily

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Hor...

3 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomit...

3 months ago - Business Wire

Horizon Therapeutics has a clear path to significant sales growth.

Other stocks mentioned: ABBV, BMY, PFE, SGEN, VRTX
3 months ago - The Motley Fool

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces new NMOSD data being presented at the American Academy of Neurology's 73rd Annual Meeting.

3 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics to resupply the market with TEPEZZA® (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED) beginning in April.

3 months ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an in...

3 months ago - Business Wire

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a clinical trial that will evaluate a monthly dosing regimen of 16 mg of KRYSTEXXA (peg...

3 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval ...

4 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual glo...

4 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela acquisition provides multipl...

Other stocks mentioned: VIE
4 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked No. 1 on the Fortune Best Workplaces in Biopharma 2021 list. This is the fifth consecutive year Horizon has bee...

4 months ago - Business Wire

About HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI ... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
Jul 28, 2011
Stock Exchange
NASDAQ
Ticker Symbol
HZNP
Full Company Profile

Financial Performance

In 2020, HZNP's revenue was $2.20 billion, an increase of 69.26% compared to the previous year's $1.30 billion. Earnings were $389.80 million, a decrease of -31.98%.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for HZNP stock is "Buy." The 12-month stock price forecast is 114.18, which is an increase of 12.99% from the latest price.

Price Target
$114.18
(12.99% upside)
Analyst Consensus: Buy